Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 11:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 307 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Atorvastatin calcium (Lipitor) Clear all
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Prothrombotic Inflammatory Markers in Women With Metabolic Syndrome - Effect of Atorvastatin

NCT01785615
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Atorvastatin, Placebo
Drug · Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2013
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 7, 2017 · Synced Oct 10, 2026, 11:27 AM EDT
Completed Early Phase 1 Interventional Results available

Pilot Study of Atorvastatin and Anakinra in Children With Coronary Artery Abnormalities Secondary to Kawasaki Disease

NCT04747847
View directory record Official record
Conditions
Kawasaki Disease
Interventions
Atorvastatin and anakinra
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
1 Year to 17 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 10, 2026, 11:27 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Impact of Statin Therapy on Adaptations to Aerobic Exercise

NCT03360916
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
Lipitor 20Mg Tablet, Lipitor 80Mg Tablet, Placebo, Exercise Program
Drug · Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
35 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Oct 10, 2026, 11:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of ASC42 With Atorvastatin

NCT05464628
View directory record Official record
Conditions
Healthy
Interventions
Atorvastatin, ASC42
Drug
Lead sponsor
Gannex Pharma Co., Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 27, 2024 · Synced Oct 10, 2026, 11:27 AM EDT
Completed Phase 3 Interventional Results available

Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study

NCT01516879
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Evolocumab, Placebo, Atorvastatin, Ezetimibe, Diet Only
Biological · Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
905 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
41
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2022 · Synced Oct 10, 2026, 11:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Of SB-751689, Atorvastatin, Ketoconazole, And Rosuvastatin In Health Postmenopausal Women.

NCT00388596
View directory record Official record
Conditions
Osteoporosis
Interventions
SB-751689
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
Up to 65 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 13, 2008 · Synced Oct 10, 2026, 11:27 AM EDT
Completed Phase 4 Interventional

To Investigate the Role of Upstream High Dose Statin in STEMI

NCT01050348
View directory record Official record
Conditions
Acute Myocardial Infarction
Interventions
Atorvastatin calcium, Inactive Placebo
Drug
Lead sponsor
The Western Pennsylvania Hospital
Other
Eligibility
25 Years to 90 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 5, 2018 · Synced Oct 10, 2026, 11:27 AM EDT
Completed Phase 1Phase 2 Interventional

Statins and Lupus: Effects of Statins on Clinical Lupus Parameters, Serological Markers and Toll-like Receptors

NCT00519363
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
atorvastatin
Drug
Lead sponsor
The Center for Rheumatic Disease, Allergy, & Immunology
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 24, 2010 · Synced Oct 10, 2026, 11:27 AM EDT
Terminated Phase 2 Interventional Results available

Mission Connect Mild Traumatic Brain Injury (TBI) Integrated Clinical Protocol

NCT01013870
View directory record Official record
Conditions
Traumatic Brain Injury, Post-traumatic Stress Disorder
Interventions
Atorvastatin, Placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Oct 10, 2026, 11:27 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH)

NCT01617655
View directory record Official record
Conditions
Hypercholesterolaemia
Interventions
Alirocumab, Placebo (for alirocumab), Lipid Modifying Therapy (LMT)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
14
States / cities
Bell Gardens, California • Newport Beach, California • Northridge, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2016 · Synced Oct 10, 2026, 11:27 AM EDT
Terminated Not applicable Interventional Results available

Effects of Statins on Lower Extremity Arterial Function Assessed by Magnetic Resonance Imaging

NCT00770679
View directory record Official record
Conditions
Diabetes
Interventions
lipitor
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years to 90 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Oct 10, 2026, 11:27 AM EDT
Terminated Phase 2 Interventional Results available

Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy

NCT03872388
View directory record Official record
Conditions
Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Estrogen Receptor Negative, HER2/Neu Negative, Inflammatory Breast Carcinoma, Progesterone Receptor Negative, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma
Interventions
Atorvastatin, Capecitabine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
5
States / cities
Gilbert, Arizona • Greeley, Colorado • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Oct 10, 2026, 11:27 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

MicroRNA Activation of LOX-1 Mechanisms in Endometriosis

NCT05331053
View directory record Official record
Conditions
Endometriosis
Interventions
Atorvastatin
Drug
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Oct 10, 2026, 11:27 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood

NCT00616772
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Heart Disease, Dyslipidemia
Interventions
ABT-335, Placebo, Atorvastatin
Drug · Other
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
45 Years and older
Enrollment
682 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
124
States / cities
Chandler, Arizona • Gilbert, Arizona • Mesa, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 10, 2026, 11:27 AM EDT
Completed Phase 3 Interventional

The Effects of Atorvastatin in Patients With Atherosclerosis

NCT00115817
View directory record Official record
Conditions
Atherosclerosis
Interventions
Atorvastatin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
21 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 24, 2007 · Synced Oct 10, 2026, 11:27 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Efficacy of Statins In Prevention of CIN

NCT01071993
View directory record Official record
Conditions
Nephropathy
Interventions
placebo, atorvastatin
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 100 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
2
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Oct 10, 2026, 11:27 AM EDT
Not listed Phase 2 Interventional

Pharmacodynamic Equivalence of Ramipril 10 mg and Atorvastatin 40 mg Administered as a Cardiovascular (CV) Polypill Acetylsalicylic Acid-Atorvastatin-Ramipril (AAR) as Compared to Monotherapy

NCT02791958
View directory record Official record
Conditions
Hypertension
Interventions
Cardiovascular Fixed Dose Combination Pill AAR, Atorvastatin 40 mg, Ramipril 10 mg
Drug
Lead sponsor
Ferrer Internacional S.A.
Industry
Eligibility
18 Years to 74 Years
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
36
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Oct 10, 2026, 11:27 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Drug Interactions of AEGR-733 on Lipid-lowering Agents

NCT00359281
View directory record Official record
Conditions
Healthy
Interventions
atorvastatin, simvastatin, ezetimibe, fenofibrate, dextromethorphan, Extended Release Niacin
Drug
Lead sponsor
Aegerion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 10, 2026, 11:27 AM EDT
Recruiting Phase 2 Interventional

Safety and Efficacy of Atorvastatin v. Placebo on HCC Risk

NCT05028829
View directory record Official record
Conditions
Liver Fibroses, Cirrhosis
Interventions
Atorvastatin 20mg, Placebo
Drug
Lead sponsor
Raymond Chung
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
2
States / cities
Boston, Massachusetts • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 10, 2026, 11:27 AM EDT
Completed Phase 4 Interventional Results available

A Multi-Risk Factor Strategy vs a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensives at Extra Risk

NCT00412113
View directory record Official record
Conditions
Dyslipidemia, Hypertension
Interventions
Amlodipine besylate, Amlodipine besylate/atorvastatin calcium single pill combination
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
21 Years and older
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
51
States / cities
Birmingham, Alabama • Mesa, Arizona • Garden Grove, California + 44 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Oct 10, 2026, 11:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy Participants

NCT06948747
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD5004, Rosuvastatin, Erythromycin, Atorvastatin, Simvastatin, Repaglinide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 10, 2025 · Synced Oct 10, 2026, 11:27 AM EDT
Completed Phase 2 Interventional Results available

A Study of LY2484595 in Patients With High LDL-C or Low HDL-C

NCT01105975
View directory record Official record
Conditions
Dyslipidemia
Interventions
LY2484595, Atorvastatin, Simvastatin, Rosuvastatin, Placebo for LY2484595, Placebo for Statins
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
38
States / cities
Fayetteville, Arkansas • San Diego, California • Spring Valley, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2018 · Synced Oct 10, 2026, 11:27 AM EDT
Completed Phase 3 Interventional Results available

Benefits of Medical Therapy Plus Stenting for Renal Atherosclerotic Lesions

NCT00081731
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Diseases, Hypertension, Renovascular, Renal Artery Obstruction
Interventions
Atacand/HCT, Caduet, GENESISTM Embolic Protection Stent and Angioguard Device (Angioplasty plus stenting)
Drug · Procedure
Lead sponsor
Baim Institute for Clinical Research
Other
Eligibility
18 Years and older
Enrollment
947 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 5, 2015 · Synced Oct 10, 2026, 11:27 AM EDT
Completed Phase 3 Interventional

To Evaluate the Safety and Effectiveness of Atorvastatin Plus a Cholinesterase Inhibitor in AD Patients.

NCT00151502
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Atorvastatin
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
40
States / cities
Sun City, Arizona • Fresno, California • Laguna Hills, California + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 10, 2026, 11:27 AM EDT